US4089960A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides
Assignee: Novartis Corp
•
Filing: 1976-09-14
•
Granted: 1978-05-16
•
Expires: 1996-09-14
Abstract
Abstract The present invention provides new basically substituted pyridinecarboxamides having the formula I ##STR1## wherein R 1 represents lower alkyl and --OR 1 is in the adjacent position to the carboxamide group, R 2 represents lower alkyl or an ethylene radical which is attached to one of the trivalent radicals designated as A and the nitrogen atom located between it to form a 6-membered ring, A represents a divalent saturated hydrocarbon radical which encompasses at most a single ring with 5 or 6 ring members and contains not more than 7 carbon atoms and whose two linkage positions are separated by (3-m) to 4 carbon atoms, or, if R 2 is an ethylene radical, represents the 1-propanyl-3-ylidene radical, if m s 1, or the 1,2,4-butane-triyl radical, if m is 0, And one of the factors m and n is 0 and the other is 1, and, if desired, the ring B is further substituted, and the acid addition salts of the compounds of the formula I. These new substances possess useful pharmacological properties, in particular antiemetic, psychosomatic and antipsychotic activity and can be used for the treatment of thought disturbances and of states of psychomotor excitation. Specific embodiments are N-[(1-ethyl-2-pyrrolidinyl)-methyl]-2,6-dimethoxynicotinamide and the pharmaceutically acceptable acid addition salts thereof.
Inventors
- 👤 Jacques Gosteli
- 👤 Angelo Storni
- 👤 Armin Zust
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 21:58
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/78; A; A61; A61P; A61P1/00; A61P1/08; A61P25/00; A61P25/18; C07D213/79; C07D213/80; C07D453/00; C07D453/02
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
170 words
A basically substituted pyridine carboxamide of the formula I ##STR6## wherein R 1 represents lower alkyl and --OR 1 is in the adjacent position to the carboxamide group, R 2 represents lower alkyl or an ethylene radical which is attached to one of the trivalent radicals designated as A and the nitrogen atom located between it to form a 6-membered ring, A represents a divalent saturated aliphatic hydrocarbon radical which contains not more than 7 carbon atoms and whose two linkage positions are separated by (3-m) to 4 carbon atoms, or, if R 2 is an ethylene radical, represents the 1-propanyl-3-ylidene radical, if m is 1, or the 1,2,4-butane-triyl radical, if m is 0, and one of the factors m and n is 0 and other is 1, and the ring B is substituted only by O--R 1 or additionally by halogen with an atomic number up to 35, by lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, di-lower alkylamino or cyano, and the acid addition salts thereof.
Claim 2
Dependent Claim
170 words
A basically substituted pyridine carboxamide of the formula I ##STR6## wherein R 1 represents lower alkyl and --OR 1 is in the adjacent position to the carboxamide group, R 2 represents lower alkyl or an ethylene radical which is attached to one of the trivalent radicals designated as A and the nitrogen atom located between it to form a 6-membered ring, A represents a divalent saturated aliphatic hydrocarbon radical which contains not more than 7 carbon atoms and whose two linkage positions are separated by (3-m) to 4 carbon atoms, or, if R 2 is an ethylene radical, represents the 1-propanyl-3-ylidene radical, if m is 1, or the 1,2,4-butane-triyl radical, if m is 0, and one of the factors m and n is 0 and other is 1, and the ring B is substituted only by O--R 1 or additionally by halogen with an atomic number up to 35, by lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, di-lower alkylamino or cyano, and the acid addition salts thereof.
Claim 3
Dependent Claim
80 words
A compound according to claim 1 having the formula I in which R 1 , R 2 , m and n are as defined in claim 1 and A represents trimethylene or, if R 2 is an ethylene radical, represents the 1-propanyl-3-ylidene radical, if m is 1, or the 1,2,4-butane-triyl radical, if m is 0, and, if desired, the ring B is substituted only by O--R 1 or additionally as defined in claim 1, and the acid addition salts thereof.
Claim 4
Dependent Claim
98 words
A compound according to claim 1 having the formula I given in claim 1, in which R 1 , R 2 , m and n are as defined in claim 1 and A represents trimethylene or, if R 2 is an ethylene radical, represents the 1-propanyl-3-ylidene radical, if m is 1, or the 1,2,4-butane-triyl radical, if m is 0, and the ring B is substituted only by O--R 1 or additionally by halogen with an atomic number up to 35, by lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl or lower alkylsulphonyl, and the acid addition salts thereof.
Claim 5
Dependent Claim
78 words
A compound according to claim 1 having the formula I given in claim 1, in which R 1 represents lower alkyl, R 2 represents lower alkyl, and A represents trimethylene, m and n are as defined in claim 1 and the ring B is substituted only by O--R 1 or additionally by halogen with an atomic number up to 35, by lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl or lower alkylsulphonyl, and the acid addition salts thereof.
Claim 6
Dependent Claim
59 words
A compound according to claim 1 having the formula I given in claim 1, in which R 1 represents methyl, R 2 represents ethyl, A represents trimethylene, m is 0 and n is 1, and the ring B is substituted only by O--R 1 or additionally by chlorine, methyl or methoxy, and the pharmaceutically acceptable acid addition salts thereof.
Claim 7
Dependent Claim
17 words
A compound according to claim 1 which is N-[(1-ethyl-2-pyrrolidinyl)-methyl]-4-methoxynicotinamide, and the pharmaceutically acceptable acid addition salts thereof.
Claim 8
Dependent Claim
17 words
A compound according to claim 1 which is N-[(1-ethyl-2-pyrrolidinyl)-methyl]-3-methoxypicolinamide, and the pharmaceutically acceptable acid addition salts thereof.
Claim 9
Dependent Claim
15 words
A compound according to claim 1 which is N-[(1-ethyl-2-pyrrolidinyl)-methyl]-3-methoxy-6-methylpicolinamide, and the pharmaceutically acceptable salts thereof.
Claim 10
Dependent Claim
17 words
A compound according to claim 1 which is N-[(1-ethyl-2-pyrrolidinyl)-methyl]-2,6-dimethoxynicotinamide, and the pharmaceutically acceptable acid addition salts thereof.
Claim 11
Dependent Claim
17 words
A compound according to claim 1 which is N-[(1-ethyl-2-pyrrolidinyl)-methyl]-2-methoxy-6-chloronicotinamide, and the pharmaceutically acceptable acid addition salts thereof.
Claim 12
Dependent Claim
15 words
A compound according to claim 1 which is N-[(2-quinuclidinyl)-methyl]-2,6-dimethoxynicotinamide, and the pharmaceutically acceptable salts thereof.
Claim 13
Dependent Claim
17 words
A compound according to claim 1 which is N-(3-quinuclidinyl)-2,6-dimethoxynicotinamide, and the pharmaceutically acceptable acid addition salts thereof.
Claim 14
Dependent Claim
79 words
An antiemetic, psychosomatic and antipsychotic pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and having the formula I ##STR7## in which R 1 , R 2 , A, m and n are as defined in claim 1 and, the ring B is substituted only by O--R 1 or additionally as defined in claim 1, or of a pharmaceutically acceptable acid addition salt thereof, together with a solid, powdery carrier or a suppository base.
Claim 15
Dependent Claim
163 words
A pharmaceutical composition according to claim 13 wherein a therapeutically effective amount of a compound having the formula I given in claim 13, in which R 1 represents lower alkyl and --OR 1 is in the adjacent position to the carboxamide group, R 2 represents lower alkyl or an ethylene radical which is attached to one of the trivalent radicals designated as A and the nitrogen atom located between it to form a 6-membered ring, A represents trimethylene or, if R 2 is an ethylene radical, represents the 1-propanyl-3-ylidene radical, if m is 1, or the 1,2,4-butane-triyl radical, if m is 0, one of the factors m and n is 0 and the other is 1, and the ring B is substituted only by O--R 1 or additionally by halogen with an atomic number up to 35, by lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, di-lower alkylamino or cyano, or of a pharmaceutically acceptable acid addition salt thereof is present.
Claim 16
Dependent Claim
72 words
A pharmaceutical composition according to claim 13 wherein a therapeutically effective amount of a compound of having the formula I given to claim 13, in which R 1 represents methyl, R 2 represents ethyl, A represents trimethylene, m is 0 and n is 1, and the ring B is substituted only by O--R 1 or additionally by chlorine, methyl or methoxy, or of a pharmaceutically acceptable acid addition salt thereof is present.
Claim 17
Dependent Claim
25 words
A pharmaceutical composition according to claim 13, wherein a therapeutically effective amount of N-[(1-ethyl-2-pyrrolidinyl)-methyl]-2,6-dimethoxynicotinamide or of a pharmaceutically acceptable acid addition salt thereof is present.
Claim 18
Dependent Claim
82 words
A method for the treatment of a state of psychomotor excitation in a warmblooded animal comprising administration to said animal of a therapeutically effective amount of a compound according to claim 1 and having the formula I ##STR8## in which R 1 , R 2 , A, m and n are as defined in claim 1 and, the ring B is substituted only by O--R 1 or additionally as defined in claim 1, or of a pharmaceutically effective acid addition salt thereof.
Claim 19
Dependent Claim
162 words
A method according to claim 17 comprising administration of a therapeutically effective amount of a compound having the formula I given in claim 17, in which R 1 represents lower alkyl and --OR 1 is in the adjacent position to the carboxamide group, R 2 represents lower alkyl or an ethylene radical which is attached to one of the trivalent radicals designated as A and the nitrogen atom located between it to form a 6-membered ring, A represents trimethylene or, if R 2 is an ethylene radical, represents the 1-propanyl-3-ylidene radical, if m is 1, or the 1,2,4-butane-triyl radical, if m is 0, one of the factors m and n is 0 and the other is 1, and the ring B is substituted only by O--R 1 or additionally by halogen with an atomic number up to 35, by lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, di-lower alkylamino or cyano, or of a pharmaceutically acceptable acid addition salt thereof.
Claim 20
Dependent Claim
70 words
A method according to claim 17 comprising administration of a therapeutically effective amount of a compound having the formula I given in claim 17, in which R 1 represents methyl, R 2 represents ethyl, A represents trimethylene, m is 0 and n is 1, and the ring B is substituted only by O--R 1 or additionally by chlorine, methyl or methoxy, or of a pharmaceutically acceptable acid addition salt thereof.
Claim 21
Dependent Claim
24 words
A method according to claim 17 comprising administration of a therapeutically effective amount of N-[(1-ethyl-2-pyrrolidinyl)-methyl]-2,6-dimethoxynicotinamide or of a pharmaceutically acceptable acid addition salt thereof.
Claim 22
Dependent Claim
78 words
An antiemetic, psychosomatic and antipsychotic pharmaceutical composition for parenteral administration which is an aqueous solution of a therapeutically effective amount of a water-soluble, pharmaceutically acceptable acid addition salt of a compound according to claim 1 having the formula I given in claim 1, in which R 1 , R 2 , A, m and n are as defined in claim 1 and the ring B is substituted only by O--R 1 or additionally as defined in claim 1.
References Cited (Backward Citations)
US2748134A
Cited
US3105072A
Cited
DE2162917A1
Cited
DE2327193A1
Cited
DE2327414A1
Cited
US3970663A
Cited
DE2452405A1
Cited
US3933830A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-05-15 | 1981-11-14 | 1982-05-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-05-15 | 1985-11-14 | 1986-05-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-05-15 | 1989-11-14 | 1990-05-16 | $7700.00 | Window Closed / Lapsed |